Thirty-seven adult Caucasian patients (9 males and 28 females), with erythemato-telangiectatic rosacea accompanied by stinging and burning sensation, were treated with a cream containing 5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan. All patients were previously treated at other centers with topical azelaic acid and/or metronidazole. The cream was applied twice daily for 12 weeks. The objective of the study was the evaluation of the soothing effect of the cream: stinging and burning sensation were measured by means of a 4-point scale (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). All patients were clinically evaluated every 4 weeks. Of 37 patients (81.1%), 30 were considered evaluable. Before the beginning of the study, the total score of stinging and burning sensation was 66 (mean: 2.2 points/patient); at the end of the study, it was 37 points (-29) (mean: 1.2 points/patient), with a reduction of 56.1%. No side effects were reported or observed. This study shows that the fixed combination potassium azeloyl diglycinate - hydroxypropyl chitosan is effective in reducing stinging and burning sensation in patients with erythemato-telangiectatic rosacea.

Download full-text PDF

Source
http://dx.doi.org/10.3109/09546634.2014.921275DOI Listing

Publication Analysis

Top Keywords

stinging burning
16
burning sensation
16
erythemato-telangiectatic rosacea
12
potassium azeloyl
12
azeloyl diglycinate
12
diglycinate hydroxypropyl
12
hydroxypropyl chitosan
12
study
5
patients
5
treatment symptoms
4

Similar Publications

Objective: This study aimed to investigate the potential relationship between the presence of mites and dermatological symptoms in patients with rosacea in the Central Anatolian Region of Türkiye.

Methods: A total of 63 patients diagnosed with rosacea were enrolled in the study. Skin samples were obtained using a standardized skin surface biopsy technique, and a questionnaire was administered to assess skin symptoms.

View Article and Find Full Text PDF

Background: Acne vulgaris (acne) is a common disorder with a complex, multi-faceted pathophysiology. To date, there has not been a single topical treatment that targets all aspects of acne pathophysiology (ie, increased sebum production, presence of , inflammation, and follicular hyperkeratinization). As such, topical treatments need to be utilized in combination to target all four of the major recognized pathophysiologic components in acne lesion formation.

View Article and Find Full Text PDF

Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes. Patients received Tapinarof or vehicle cream QD for 8 weeks.

View Article and Find Full Text PDF

Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials. Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.

View Article and Find Full Text PDF

Background: There is continuous demand for safe, effective cosmetic ingredients to treat the signs of aging skin, including fine lines, wrinkles, brown spots, discoloration, laxity, and sagging. While there are a plethora of cosmeceutical peptides, few combine anti-aging and anti-inflammatory benefits with small size.

Methods: Preclinical and clinical studies evaluated the anti-inflammatory properties, anti-aging benefits, and tolerability of acetyl dipeptide-31 amide (AP31), a novel, small, anti-aging micropeptide, to understand its impact as a multifaceted, cosmetic, anti-aging, and anti-inflammaging ingredient.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!